SCHEMBL1783042

SCHEMBL1783042

CCCCCCC(C)CCC=O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.56
ACE2 Q9BYF1 1/20 0.52
FAAH O00519 2/20 0.50
TRPV1 Q8NER1 2/20 0.50
ADH1B P00325 2/20 0.48
ADH1C P00326 2/20 0.48
ADH1A P07327 2/20 0.48
ADH4 P08319 2/20 0.48
ADH7 P40394 2/20 0.48
EPHX1 P07099 1/20 0.41
ALDH1A1 P00352 1/20 0.40
OPRM1 P35372 1/20 0.39
TRPA1 O75762 1/20 0.38
DDAH1 O94760 1/20 0.38
GAPDH P04406 1/20 0.38
MAPT P10636 1/20 0.38
FDPS P14324 3/20 0.38
GPR84 Q9NQS5 2/20 0.38
PRKD3 O94806 1/20 0.38
PRKCG P05129 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28194813 1.00 TSHR (0.56) TSHRACE2FAAHTRPV1ADH1B
SCHEMBL13309277 1.00 TSHR (0.56) TSHRACE2FAAHTRPV1ADH1B
SCHEMBL13309278 1.00 TSHR (0.56) TSHRACE2FAAHTRPV1ADH1B
SCHEMBL27577002 1.00 TSHR (0.56) TSHRACE2FAAHTRPV1ADH1B
SCHEMBL11358374 1.00 TSHR (0.56) TSHRACE2FAAHTRPV1ADH1B
SCHEMBL1410356 0.98 TSHR (0.52) TSHRACE2FAAHTRPV1ADH1B
SCHEMBL31132197 0.92 TSHR (0.52) TSHRACE2FAAHTRPV1ADH1B
SCHEMBL23925001 0.91 TSHR (0.70) TSHRACE2FAAHTRPV1ADH1B
SCHEMBL9544428 0.91 TSHR (0.70) TSHRACE2FAAHTRPV1ADH1B
SCHEMBL21380134 0.91 TSHR (0.70) TSHRACE2FAAHTRPV1ADH1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-103113295-A Alkyl-substituted quinolinone compound with side chains as well as preparation method, pharmaceutical composition and application thereof UNIV CHONGQING TECHNOLOGY 2013-05-22 CN claimed
CN-106999973-A System and method for discharging edible material 阿甘芳香和精细化工有限公司 2017-08-01 CN disclosed
CN-102241720-B L-nucleic acid derivative and processes for the synthesis thereof MITSU CHEMICALS INC 2014-01-29 CN disclosed
US-8632792-B2 Cooling sensation agent composition and sensory stimulation agent composition TAKASAGO INTERNATIONAL CORPORATION (JP) 2014-01-21 US disclosed
CN-103113295-A Alkyl-substituted quinolinone compound with side chains as well as preparation method, pharmaceutical composition and application thereof UNIV CHONGQING TECHNOLOGY 2013-05-22 CN disclosed
CN-101250208-B L-nucleic acid derivative and processes for the synthesis thereof MITSU CHEMICALS INC 2012-06-20 CN disclosed
CN-102241720-A L-nucleic acid derivative and processes for the synthesis thereof MITSU CHEMICALS INC 2011-11-16 CN disclosed
US-20110117147-A1 COOLING SENSATION AGENT COMPOSITION AND SENSORY STIMULATION AGENT COMPOSITION TAKASAGO INTERNATIONAL CORPORATION (JP) 2011-05-19 US disclosed
EP-1348712-B1 Processes and intermediates in the synthesis of L-thymidine MITSUI CHEMICALS INC (JP) 2011-05-04 EP disclosed
CN-101250194-B L-nucleic acid derivative and processes for the synthesis thereof MITSUI CHEMICALS INC 2011-05-04 CN disclosed
EP-0251827-B1 NEW CYCLIC ETHER DERIVATIVES, THEIR PREPARATION AND THEIR USE Sankyo Company Limited (JP) 1993-09-15 EP disclosed
CN-1072686-A Has Pyrmidine nucleoside derivatives of anti-tumor activity and its production and use SANKYO CO (JP) 1993-06-02 CN disclosed
EP-0536936-A1 Pyrimidine nucleoside derivatives having anti-tumor activity, their preparation and use Sankyo Company Limited (JP) 1993-04-14 EP disclosed
CN-1059720-A Radicicol derivatives, its preparation method and anti-tumor activity thereof SANKYO CO (JP) 1992-03-25 CN disclosed
WO-1991018905-A1 RADICICOL DERIVATIVES, THEIR PREPARATION AND THEIR ANTI-TUMOR ACTIVITY SANKYO COMPANY LIMITED (JP) 1991-12-12 WO disclosed
EP-0460950-A1 Radicicol derivatives, their preparation and their anti-tumour activity Sankyo Company Limited (JP) 1991-12-11 EP disclosed
EP-0437016-A2 Lipid A analogues having immunoactivating and anti-tumour activity Sankyo Company Limited (JP) 1991-07-17 EP disclosed
CN-1052481-A Lipoid category-A with immunocompetence and anti-tumor activity is like thing SANKYO CO (JP) 1991-06-26 CN disclosed
US-4891363-A PLATELET ACTIVATING FACTOR ANTAGONISTS SANKYO COMPANY LIMITED (JP) 1990-01-02 US disclosed
EP-0251827-A2 New cyclic ether derivatives, their preparation and their use Sankyo Company Limited (JP) 1988-01-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110117147-A1 COOLING SENSATION AGENT COMPOSITION AND SENSORY STIMULATION AGENT COMPOSITION TRPA1, HRH1, HRH2 TSHR 2479/4885ACE2 4401/4885FAAH 94/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.